A groundbreaking study from the University of Surrey has uncovered an unexpected metabolic interaction between different forms of vitamin D supplementation. Researchers discovered that vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol) compete for the same metabolic enzymes, with D2 potentially interfering with the body’s processing of the more bioactive D3 form. The findings, published in The Journal of Steroid Biochemistry and Molecular Biology, revealed a 25% reduction in vitamin D3 levels when patients took D2 supplements. This discovery is particularly significant given D3’s superior role in immune function and calcium absorption. Dr. Susan Fraser, who led the research team, emphasized that these findings challenge long-standing assumptions about vitamin D supplementation that have guided clinical practice for decades. The research suggests that supplementation strategies may require reevaluation to optimize health outcomes.
Was this article helpful?
